1200 Liberty Ridge Drive, Suite 310
Chaperone Technologies Inc.
More than 70% of the bacteria that cause hospital-acquired infections are resistant to at least one of the broad-spectrum antibiotics most commonly used to treat them. By targeting peptides at a single vital intracellular structure found in all microbes, Chaperone Technologies hopes to solve the drug resistance problem for good.
More from Archive
More from Scrip
• By
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.